Overview

Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial

Status:
Active, not recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
This is a multicenter study assessing the efficacy of different therapeutic strategy in patients with advanced sarcomas.
Phase:
Phase 2
Details
Lead Sponsor:
Institut Bergonié
Collaborators:
Immune Design
Merck Sharp & Dohme Corp.
Ministry of Health, France
Treatments:
Cyclophosphamide
Pembrolizumab